

Supplementary Data

Designing a Topical Nanoliposomal Formulation of Ruxolitinib Phosphate

Atefeh Naeimifar¹, Saman Ahmad Nasrollahi^{2*}, Hamid Akbari Javar¹, Mansoor Nassiri Kashani², Alireza Firooz², Mohamadreza Rouini¹

¹*Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran*

²*Pharmaceutical, Cosmeceutical and Hygienic Formulation Lab, Center for Research & Training in Skin Diseases & Leprosy, Tehran University of Medical Sciences, Tehran, Iran*

*Corresponding author: Saman Ahmad Nasrollahi PharmD, PhD

Center for Research & Training in Skin Diseases & Leprosy (CRTSDL),

Tehran University of Medical Sciences (TUMS)

415 Taleqani Ave, Tehran, Iran

Tel: (+9821)88963804

Fax: (+9821)88963804

Email address: snasrollahi@tums.ac.ir

ORCID ID: <https://orcid.org/0000-0002-7384-6686>




Figure S1. DSC graphs of A) cholesterol, B) lecithin, C) ruxolitinib powder, D) ruxolitinib free nanoliposomes, and E) RuxoLip.

Table S1. Analytical validation results of ruxolitinib assessments A) LOD and LOQ, B) precision, C) accuracy, and D) solution stability.

A							
	Mean \pm SD			RSD%			
LOD	0.34 \pm 0.00			1.30			
LOQ	1.02 \pm 0.92			2.43			
B							
	Intra-day precision			Inter-day precision			
Con (μ /ml)	Absorbance measured		RSD %	Absorbance measured		RSD %	
	Mean \pm SD			Mean \pm SD			
2 μ /ml	0.06 \pm 0.00		7.69	0.06 \pm 0.00		1.64	
6 μ /ml	0.14 \pm 0.00		1.58	0.15 \pm 0.00		1.98	
10 μ /ml	0.22 \pm 0.00		3.58	0.22 \pm 0.00		1.42	
C							
Con (μ /ml)	1	2	3	Mean \pm SD	Calculated con	Recovery %	Limit
2 μ /ml	0.06	0.06	0.07	0.06 \pm 0.00	2.07	103.73	97-103%
6 μ /ml	0.14	0.14	0.14	0.14 \pm 0.00	6.10	101.74	97-103%
10 μ /ml	0.22	0.23	0.21	0.22 \pm 0.00	3.58	102.32	97-103%
D							
Con (μ /ml)	Initial	4 hr	8 hr	24 hr	Mean \pm SD	RSD %	
6 μ /ml	0.14	0.14	0.15	0.14	0.14 \pm 0.00	1.23	